Stephen L. Sabba net worth and biography

Stephen Sabba Biography and Net Worth

Director of Ligand Pharmaceuticals

Stephen L. Sabba, M.D., has served as a member of our board of directors since August 2008. Dr. Sabba has been a leading Bio/Pharma Analyst and Fund Manager for Knott Partners, L.P., an investment fund company, since November 2006. Previously he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based Health Care hedge fund. Prior to that, Dr. Sabba was Director of Research at Sturza’s Medical Research, and previously was a gastroenterologist and internist in private practice at Phelps Hospital in North Tarrytown, New York. He received his M.D. from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. with honors at Cornell University. Dr. Sabba served as a member of the board of the directors for Novelion Therapeutics Inc., a leading Canadian biotech company from June 2012 to January 2020.

What is Stephen L. Sabba's net worth?: The estimated net worth of Stephen L. Sabba is at least $5.45 million as of March 5th, 2024. Dr. Sabba owns 28,926 shares of Ligand Pharmaceuticals stock worth more than $5,452,551 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Sabba may own. Learn More about Stephen L. Sabba's net worth.
How do I contact Stephen L. Sabba?: The corporate mailing address for Dr. Sabba and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at [email protected]. Learn More on Stephen L. Sabba's contact information.
Has Stephen L. Sabba been buying or selling shares of Ligand Pharmaceuticals?: Stephen L. Sabba has not been actively trading shares of Ligand Pharmaceuticals during the last ninety days. Most recently, Stephen L. Sabba sold 1,893 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $74.30, for a transaction totalling $140,649.90. Following the completion of the sale, the director now directly owns 28,926 shares of the company's stock, valued at $2,149,201.80. Learn More on Stephen L. Sabba's trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Todd Davis (CEO), Octavio Espinoza (CFO), Matthew Foehr (COO), Nancy Gray (Director), John Higgins (CEO), John Kozarich (Director), John LaMattina (Director), Andrew Reardon (Chief Legal Officer), and Stephen Sabba (Director). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, Ligand Pharmaceuticals insiders bought shares 2 times. They purchased a total of 11,010 shares worth more than $1,156,542.00. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 22,373 shares worth more than $3,264,991.97. The most recent insider tranaction occured on December, 1st when Director John W Kozarich sold 467 shares worth more than $91,457.28. Insiders at Ligand Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 12/1/2025.

Stephen L. Sabba Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2024	Sell	1,893	$74.30	$140,649.90	28,926
5/10/2023	Sell	6,408	$77.13	$494,249.04	25,784
3/12/2018	Sell	622	$180.73	$112,414.06	26,363
12/20/2017	Sell	925	$137.25	$126,956.25	26,985

Stephen L. Sabba Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $188.50

$187.87

$194.90

50 Day Range

MA: $191.39

$169.72

$209.29

2 Week Range

Now: $188.50

$93.58

$212.49

Volume

194,343 shs

Average Volume

226,796 shs

Market Capitalization

$3.71 billion

P/E Ratio

91.06

Dividend Yield

N/A

Beta

0.99